Table 1 Clinical features and metastatic sites of metastatic gallbladder adenocarcinoma patients diagnosed between 2010 and 2016
Characteristic | Bone metastases | Brain metastases | Liver metastases | Lung metastases | Distant lymph node metastases | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes | No | P value | Yes | No | P value | Yes | No | P value | Yes | No | P value | Yes | No | P value | |
Age | |||||||||||||||
< 60 | 38 (35.5%) | 352 (24.8%) | P = 0.601 | 9 (56.3%) | 381 (25.2%) | P = 0.069 | 266 (25.2%) | 124 (26.3%) | P = 0.543 | 50 (24.6%) | 340 (25.7%) | P = 0.205 | 79 (31.1%) | 311 (24.4%) | P = 0.020 |
60–69 | 34 (31.8%) | 426 (30.0%) | 3 (18.8%) | 457 (30.3%) | 314 (29.8%) | 146 (30.9%) | 53 (26.1%) | 407 (30.8%) | 73 (28.7%) | 387 (30.4%) | |||||
70–79 | 22 (20.6%) | 396 (27.9%) | 2 (12.5%) | 416 (27.5%) | 286 (27.1%) | 132 (28.0%) | 68 (33.5%) | 350 (26.5%) | 73 (28.7%) | 345 (27.1%) | |||||
≥ 80 | 13 (12.1%) | 245 (17.3%) | 2 (12.5%) | 256 (17.0%) | 188 (17.8%) | 70 (14.8%) | 32 (15.8%) | 226 (17.1%) | 29 (11.4%) | 229 (18.0%) | |||||
Gender | |||||||||||||||
Male | 39 (36.4%) | 425 (30.0%) | P = 0.165 | 7 (43.8%) | 457 (30.3%) | P = 0.259 | 39 (36.4%) | 425 (30.0%) | P = 0.954 | 70 (34.5%) | 394 (29.8%) | P = 0.179 | 90 (35.4%) | 374 (29.4%) | P = 0.059 |
Female | 68 (63.6%) | 994 (70.0%) | 9 (56.3%) | 1053 (69.7%) | 68 (63.6%) | 994 (70.0%) | 133 (65.5%) | 929 (70.2%) | 164 (64.6%) | 898 (70.6%) | |||||
Marriage | |||||||||||||||
Married | 67 (62.6%) | 751 (52.9%) | P = 0.132 | 10 (62.5%) | 808 (53.5%) | P = 0.601 | 556 (52.8%) | 262 (55.5%) | P = 0.603 | 104 (51.2%) | 714 (54.0%) | P = 0.766 | 138 (54.3%) | 680 (53.5%) | P = 0.923 |
Unmarried | 36 (33.6%) | 616 (43.4%) | 5 (31.3%) | 647 (42.8%) | 459 (43.5%) | 193 (40.9%) | 91 (44.8%) | 561 (42.4%) | 106 (41.7%) | 546 (42.9%) | |||||
Unknown | 4 (3.7%) | 52 (3.7%) | 1 (6.3%) | 55 (3.6%) | 39 (3.7%) | 17 (3.6%) | 8 (3.9%) | 48 (3.6%) | 10 (3.9%) | 46 (3.6%) | |||||
Race | |||||||||||||||
White | 82 (76.6%) | 1061 (74.8%) | P = 0.731 | 13 (81.3%) | 1130 (74.8%) | P = 0.062 | 775 (73.5%) | 368 (78.0%) | P = 0.172 | 156 (76.8%) | 987 (74.6%) | P = 0.659 | 185 (72.8%) | 958 (75.3%) | P = 0.421 |
Black | 16 (15.0%) | 205 (14.4%) | 0 (0.0%) | 221 (14.6%) | 162 (15.4%) | 59 (12.5%) | 29 (14.3%) | 192 (14.5%) | 36 (14.2%) | 185 (14.5%) | |||||
Others | 9 (8.4%) | 153 (10.8%) | 3 (18.8%) | 159 (10.5%) | 117 (11.1%) | 45 (9.5%) | 18 (8.9%) | 144 (10.9%) | 33 (13.0%) | 129 (10.1%) | |||||
Grade | |||||||||||||||
I | 2 (1.9%) | 47 (3.3%) | P = 0.107 | 0 (0.0%) | 49 (3.2%) | P = 0.263 | 23 (2.2%) | 26 (5.5%) | P = 0.01 | 5 (2.5%) | 44 (3.3%) | P = 0.236 | 4 (1.6%) | 45 (3.5%) | P = 0.059 |
II | 11 (10.3%) | 257 (18.1%) | 1 (6.3%) | 267 (17.7%) | 171 (16.2%) | 97 (20.6%) | 30 (14.8%) | 238 (18.0%) | 49 (19.3%) | 219 (17.2%) | |||||
III + IV | 30 (28.0%) | 385 (27.1%) | 7 (43.8%) | 408 (27.0%) | 293 (27.8%) | 122 (25.8%) | 49 (24.1%) | 366 (27.7%) | 57 (22.4%) | 358 (28.1%) | |||||
Unknown | 64 (59.8%) | 730 (51.4%) | 8 (50.0%) | 786 (52.1%) | 567 (53.8%) | 227 (48.1%) | 119 (58.6%) | 675 (51.0%) | 144 (56.7%) | 650 (51.1%) | |||||
T stage | |||||||||||||||
T1 | 5 (4.7%) | 15 (1.1%) | P = 0.020 | 2 (12.5%) | 18 (1.2%) | P = 0.159 | 13 (1.2%) | 7 (1.5%) | P = 0.007 | 7 (3.4%) | 13 (1.0%) | P = 0.015 | 9 (3.5%) | 11 (0.9%) | P = 0.017 |
T2 | 6 (5.6%) | 114 (8.0%) | 1 (6.3%) | 119 (7.9%) | 90 (8.5%) | 30 (6.4%) | 21 (10.3%) | 99 (7.5%) | 17 (6.7%) | 103 (8.1%) | |||||
T3 | 10 (9.3%) | 174 (12.3%) | 2 (12.5%) | 182 (12.1%) | 122 (11.6%) | 62 (13.1%) | 16 (7.9%) | 168 (12.7%) | 22 (8.7%) | 162 (12.7%) | |||||
T4 | 43 (40.2%) | 643 (45.3%) | 4 (25.0%) | 682 (45.2%) | 453 (43.0%) | 233 (49.4%) | 89 (43.8%) | 597 (45.1%) | 117 (46.1%) | 569 (44.7%) | |||||
TX | 4 (3.7%) | 97 (6.8%) | 1 (6.3%) | 100 (6.6%) | 63 (6.0%) | 38 (8.1%) | 9 (4.4%) | 92 (7.0%) | 21 (8.3%) | 80 (6.3%) | |||||
Unknown | 39 (36.4%) | 376 (26.5%) | 6 (37.5%) | 409 (27.1%) | 313 (29.7%) | 102 (21.6%) | 61 (30.0%) | 354 (26.8%) | 68 (26.8%) | 347 (27.3%) | |||||
N stage | |||||||||||||||
N0 | 49 (45.8%) | 635 (44.7%) | P = 0.0295 | 4 (25.0%) | 680 (45.0%) | P = 0.272 | 443 (42.0%) | 241 (51.1%) | P = 0.002 | 77 (37.9%) | 607 (45.9%) | P = 0.068 | 53 (20.9%) | 631 (49.6%) | P < 0.001 |
N1 | 21 (19.6%) | 385 (27.1%) | 4 (25.0%) | 402 (26.6%) | 303 (28.7%) | 103 (21.8%) | 69 (34.0%) | 337 (25.5%) | 84 (33.1%) | 322 (25.3%) | |||||
N2 | 17 (15.9%) | 180 (12.7%) | 4 (25.0%) | 193 (12.8%) | 132 (12.5%) | 65 (13.8%) | 25 (12.3%) | 172 (13.0%) | 88 (34.6%) | 109 (8.6%) | |||||
NX | 20 (18.7%) | 219 (15.4%) | 4 (25.0%) | 235 (15.6%) | 176 (16.7%) | 63 (13.3%) | 32 (15.8%) | 207 (15.6%) | 29 (11.4%) | 210 (16.5%) | |||||
Surgery at primary site | |||||||||||||||
Yes | 26 (24.3%) | 504 (35.5%) | P = 0.016 | 4 (25.0%) | 526 (34.8%) | P = 0.399 | 337 (32.0%) | 193 (40.9%) | P = 0.001 | 38 (18.7%) | 492 (37.2%) | P < 0.001 | 57 (22.4%) | 473 (37.2%) | P < 0.001 |
No | 81 (75.7%) | 915 (64.5%) | 12 (75.0%) | 984 (65.2%) | 717 (68.0%) | 279 (59.1%) | 165 (81.3%) | 831 (62.8%) | 197 (77.6%) | 799 (62.8%) | |||||
Radiation | |||||||||||||||
Yes | 31 (29.0%) | 78 (5.5%) | P < 0.001 | 11 (68.8%) | 98 (6.5%) | P < 0.001 | 67 (6.4%) | 42 (8.9%) | P = 0.080 | 16 (7.9%) | 93 (7.0%) | P = 0.665 | 25 (9.8%) | 84 (6.6%) | P = 0.079 |
No | 76 (71.0%) | 1341 (94.5%) | 5 (31.3%) | 1412 (93.5%) | 987 (93.6%) | 430 (91.1%) | 187 (92.1%) | 1230 (93.0%) | 229 (90.2%) | 1188 (93.4%) | |||||
Chemotherapy | |||||||||||||||
Yes | 58 (54.2%) | 750 (52.9%) | P = 0.787 | 10 (62.5%) | 798 (52.8%) | P = 0.438 | 538 (51.0%) | 270 (57.2%) | P = 0.026 | 111 (54.7%) | 697 (52.7%) | P = 0.596 | 161 (63.4%) | 647 (50.9%) | P < 0.001 |
No | 49 (45.8%) | 669 (47.1%) | 6 (37.5%) | 712 (47.2%) | 516 (49.0%) | 202 (42.8%) | 92 (45.3%) | 626 (47.3%) | 93 (36.6%) | 625 (49.1%) | |||||
Tumor size | |||||||||||||||
< 3 | 11 (10.3%) | 201 (14.2%) | P = 0.167 | 3 (18.8%) | 209 (13.8%) | P = 0.183 | 132 (12.5%) | 80 (16.9%) | P = 0.122 | 30 (14.8%) | 182 (13.8%) | P = 0.046 | 35 (13.8%) | 177 (13.9%) | P = 0.998 |
< 5 | 12 (11.2%) | 197(13.9%) | 0 (0.0%) | 209 (13.8%) | 142 (13.5%) | 67 (14.2%) | 22 (10.8%) | 187 (14.1%) | 34 (13.4%) | 175 (13.8%) | |||||
≥ 5 | 15 (14.0%) | 263 (18.5%) | 3 (18.8%) | 275 (18.2%) | 195 (18.5%) | 83 (17.6%) | 26 (12.8%) | 252 (19.0%) | 47 (18.5%) | 231 (18.2%) | |||||
Unknown | 69 (64.5%) | 758 (53.4%) | 10 (62.5%) | 817 (54.1%) | 585 (55.5%) | 242 (51.3%) | 125 (61.6%) | 702 (53.1%) | 138 (54.3%) | 689 (54.2%) | |||||